How Dendreon's (NASDAQOTH:DNDNQ) drug Provenge performs in sequence with Johnson & Johnson's drug Zytiga to treat advanced stage prostate cancer is crucial to the company's near- to mid-term success. In this video, Motley Fool health care analyst David Williamson discusses the possible outcomes and how Dendreon will move forward if the clinical trial is a failure.
David Williamson and Max Macaluso haveno position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.